Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PTAFR | P25105 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6514840 | 0.80 | KMT2A (0.36) | DRD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6509056 | 0.78 | ATR (0.34) | — | |
| SCHEMBL6515376 | 0.78 | MAPT (0.41) | DRD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6514298 | 0.76 | RET (0.34) | — | |
| SCHEMBL6509485 | 0.76 | GAA (0.36) | — | |
| SCHEMBL6517970 | 0.72 | CHEK1 (0.36) | — | |
| SCHEMBL6511094 | 0.67 | CHEK1 (0.41) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6514165 | 0.67 | CHEK1 (0.39) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6522000 | 0.66 | CHEK1 (0.41) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6511866 | 0.66 | CHEK1 (0.38) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | PGK1 119/4885DRD1 4838/4885CYP1A2 4825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.